Respironics' injunction against AirSep upheld:
This article was originally published in Clinica
Executive Summary
An appellate court in the US has upheld Respironics' preliminary injunction in a patent infringement suit against AirSep. As a result, AirSep, of Buffalo, New York, is prohibited from manufacturing, distributing and selling any device which uses Respironics' bi-level airway pressure technology, including bi-level devices for the treatment of obstructive sleep apnoea. The decision affirms a ruling from November 1997 by the US district court for the Western District of Pennsylvania. Pittsburg, Pennsylvania-based Respironics is the market leader in the obstructive sleep apnoea treatment market.